English transcript

33-year-old woman, October 2021, stage 4 breast cancer, and I've listed all this here. I'll put

this all in the notes so you can follow the story for yourself in the description.

So, stage 4 breast cancer, in other words, it's spread around the body, metastatic disease.

She'd initially been diagnosed with breast cancer in 2009, but she'd been treated,

she'd had a bilateral mastectomy in 2009 and other treatments, and she did well for a while,

but then the disease recurred in 2021. A liver biopsy confirmed metastatic breast malignancy,

in other words, had spread to a liver. Now, we say if it's spread to your liver or your bones,

basically that's basically a death sentence, normally. So, this is spread to a liver,

confirmed metastasis. Acidic fluid, so ascites is the swelling in the abdomen you get as a result

of cancer and other things, but that confirmed metastatic breast cancer, when you take the fluid

from the abdomen through a tap in the wall of the abdomen, you send it for cytology and you

could see malignant cells. Now, magnetic resonance imaging, MRI of the spine, October 21, metastatic

breast cancer in T12, that's thoracic 12, thoracic 10 vertebrae, lumbar 1, lumbar 2,

lumbar 3, lumbar 4, lumbar 5, sacral 1, sacral 2 and the iliac bones. In other words, this had

spread to a liver and her bones, clearly an intractable terminal diagnosis by all criteria.

It was all over the place, basically. A PET scan. Now, a PET scan indicates metabolic activity,

given a radioactive isotope and it detects metabolic activity. And of course, cancer is

very metabolically active, so that would light up. So, a PET scan on the 29th of December 2021 showed

six hypermetabolic lung lesions and the largest was 2.8 by 1.5 centimetres. In other words,

it was in a lungs. So, it was in a spine, in a lungs, in a liver, this was everywhere.

Hypermetabolic bone lesions, biggest was 5 by 2.9 centimetres.

Analytic lesion, that just means basically see a hole in L4 extended to the spinal canal area.

Patient declined further conventional chemotherapy or radiation therapy and

was placed under hospice care. So, basically, end of life care.

Now, you might need to look at the notes to follow this accurately, but I've got it all here.

November 22nd, 2021, she started self-administering fenbendazole at a daily

dose of 222 milligrams. So, she just basically started giving herself fenben. In December 2021,

she received another injection to block oestrogen, intended to inhibit cancer growth. So,

you've got a bit of a complication there. You've got two treatments going on at once, but

to give an oestrogen blocker at this stage would not, under normal circumstances, be curative.

Anyway, moving on to 2022 in January, she did have targeted radiation for two spinal metastases.

Spinal metastases are horrible, can press on the spinal cord and on the main nerves,

the pain can be indescribably bad. Nerve pain is, you really don't want nerve pain.

So, she had radiotherapy for that, but that would only affect where the radiation targeted. It

wouldn't affect the liver, it wouldn't affect the lungs, it wouldn't affect the other vertebrae.

These tumors disappeared rapidly, relieving the pain within a few days. So, very effective

palliative treatment, but not curative because it wouldn't affect the cancer in other parts of the

body. Continued taking 222 milligrams of fenbendazole a day for eight months. During this

time, her liver enzymes normalized. So, the cancer was in the liver, that would alter her liver

but the liver enzymes went back to normal. Now, something called CA2729 is a tumor marker.

That dropped from 316 in November 2021 and then in July 2022, so what, seven months later,

it was down to 36.6, indicating there was massively less tumor in her body. Then April

2022, a PET scan, again, looking at the metabolic activity, confirmed the absence of any abnormal

metabolic activity indicative of cancer. Quite staggering. So, it was in her lungs,

it was in her vertebrae, it was in her pelvis, it was in her liver, and yet after, what, eight

months of fenbendazole, the PET scan confirmed the absence of any abnormal metabolic activity

indicative of cancer.